麻豆传媒

Pulmonology >

Lung Cancer

News, opinions and meeting coverage in pulmonology.

FDA APPROVED osimertinib (Tagrisso) over a computer rendering of lung cancer.

FDA Expands Approval of Osimertinib in Lung Cancer

EGFR inhibitor now indicated for unresectable stage III disease following chemoradiotherapy

A photo of test tubes of blood lying on a test form with CANCER stamped in red at the bottom.

Cancer Diagnoses Slow to Recover From Effects of COVID Pandemic

Actual rates for 2021 lagged behind projections

WCLC over a photo of San Diego Conference Center in San Diego, CA.

Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC

Objective response rate was 55% with 12-mg/kg ifinatamab deruxtecan

WCLC over a photo of San Diego Conference Center in San Diego, CA.

Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC

However, plinabulin plus docetaxel still "not ready for prime time," expert says

WCLC over a photo of San Diego Conference Center in San Diego, CA.

MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC

Absolute improvement of almost 30%, doubling of duration of response with savolitinib

WCLC over a photo of San Diego Conference Center in San Diego, CA.

Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC

Two-trial analysis shows about a 40% decreased risk of disease recurrence or death

WCLC over a photo of San Diego Conference Center in San Diego, CA.

Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC

Novel agent nearly halved risk of progression as first-line therapy in phase III trial

WCLC over a photo of San Diego Conference Center in San Diego, CA.

Novel Drugs Boost Immunotherapy Activity in Resectable Lung Cancer

Add-on ADC, monoclonal antibody consistently increase pCR versus PD-1 inhibitor plus chemotherapy

A photo composite of vials of Opdivo and Yervoy over a computer rendering of lung cancer.

Trial Questions Role of Dual Immunotherapy in First-Line NSCLC

In Japanese trial, nivolumab-ipilimumab didn't improve OS versus pembrolizumab, had more toxicity

A CT scan of healthy lungs.

Researchers Challenge USPSTF's Lung Cancer Screening Criteria

Alternate criteria based on years of smoking has higher sensitivity and specificity, study says

FDA APPROVED lazertinib (Lazcluze) over a computer rendering of lung cancer.

Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer

Lazertinib plus amivantamab improved PFS by about 7 months versus single-agent osimertinib

A photo of a box of prednisolone tablets.

Higher Steroid Dose for ICI Toxicity Harms Cancer Survival, Analysis Suggests

More data for discussion of controversial association between steroids, immunotherapy

FDA APPROVED durvalumab (Imfinzi) over a computer rendering of a transparent body with lung cancer highlighted.

FDA Expands Durvalumab Label to Operable Lung Cancer

PD-L1 checkpoint inhibitor approved for use in NSCLC before and after surgery

A computer rendered cutaway of a colonoscopy.

Cancer Screening Costs Over $43 Billion a Year in the U.S., Study Estimates

Colorectal cancer screening accounted for 64% of the total amount

FDA ODAC durvalumab (Imfinzi) over a computer rendering of an antibody attacking lung cancer cells.

FDA Panel Supports More Clarity in NSCLC Perioperative Immunotherapy Trials

Committee unanimously backs mandating trial design to distinguish effects of therapy phases

A close up photo of a man smoking an ecigarette.

Vapers May Be Less Likely to Undergo Lung Cancer Screening

"Former smokers who use e-cigarettes remain at increased risk of lung cancer," researchers say

A computer rendering of a liver under a red umbrella.

Real-World Analysis Identifies Meds Tied to Higher Risk of Liver Injury

Case reports may not be as reliable, researchers say

A photo of the HealthCare.gov website.

Court: Some Employers Can Exclude PrEP, Cancer Screenings From Insurance Coverage

Not all preventive care recommended by the USPSTF is threatened by the narrow ruling, however

A computer rendering of a transparent body with a tumor in the lungs highlighted.

Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLC

No significant difference between atezolizumab-cabozantinib, docetaxel for OS, PFS, response

A close up photo of a woman smoking a cigarette.

Early Menopause Tied to Higher Risk of Respiratory Mortality

Greatest risk observed for women with bilateral oophorectomy

A computer rendering of a lung tumor.

Another KRAS Inhibitor Scores an Early Win in Advanced Non-Small Cell Lung Cancer

Half of patients responded, but editorialists call for new directions in therapy development

A scanning electron microscope image of a dendritic cell

Dendritic Cell Therapy Offers No Survival Advantage in Pleural Mesothelioma

Immunotherapy may have been given too late, researchers suggested

An advertisement for lung cancer screening on the back of a kiosk in New York City.

Lung Cancer Screening Rates Remain Low in the U.S., Especially in the South

But one study showed that patient navigation added to usual care may increase uptake

Artery Inflammation and CV Events; Stepped Palliative Care for Lung Cancer Patients

Also in TTHealthWatch: diets and medicine in IBS and active surveillance in prostate cancer

ASCO over a photo of McCormick Place in Chicago, IL

Limited-Stage SCLC Gets a New Standard of Care With Consolidation Durvalumab

Median OS was 55.9 months in the durvalumab group compared with 33.4 months in the placebo group

ASCO over a photo of McCormick Place in Chicago, IL

'Practice Changing' Trial for Inoperable Locally Advanced NSCLC

EGFR testing now needed for all patients with stage III disease, experts say

ASCO over a photo of McCormick Place in Chicago, IL

Virtual and In-Person Palliative Care Equally Beneficial in Advanced Lung Cancer

No differences observed in quality of life metric, patient and caregiver satisfaction

ASCO over a photo of McCormick Place in Chicago, IL

Subcutaneous Amivantamab Plus Lazertinib Non-Inferior to IV Dosing in NSCLC

Unexpectedly offers a possible overall survival benefit, researchers say

ASCO over a photo of McCormick Place in Chicago, IL

Novel Bispecific in EGFR-Mutant Lung Cancer Boosts PFS After Targeted Agents

China-based trial may present a hurdle to FDA approval, however

ASCO over a photo of McCormick Place, in Chicago, IL

Unprecedented PFS Results in ALK-Positive Lung Cancer Trial

"We have not seen anything close to this," says expert

A close up photo of a man vaping.

Smoking Isn't the Only Source of Nicotine Addiction in Town

Emerging data suggest pharmacological interventions may help patients quit vaping

A close up photo of methylphenidate tablets.

Psychostimulant No Help in Relieving Cancer-Related Fatigue

No significant differences in outcomes between methylphenidate, placebo

FDA APPROVED tarlatamab (Imdelltra) over a computer rendering of small cell lung cancer

FDA OKs Novel BiTE Agent for Small Cell Lung Cancer

First-in-class tarlatamab achieved a 40% ORR in previously treated extensive-stage SCLC

A photo of the vial and packaging of nivolumab (Opdivo) over a computer rendering of lung cancer.

Perioperative Nivolumab Boosts EFS in Resectable Lung Cancer

CheckMate 77T trial shows 42% reduction in risk of tumor recurrence, progression, or death

A photo of Dr. Laurie Margolies demonstrating the Koios DS Smart Ultrasound software

Will AI Replace Radiologists, or Just Make Them Better Than Ever?

Opinions differ on how much physicians should be embracing the technology

A computer rendering of KRAS G12C mutation in non-small cell lung cancer

Glecirasib Shows Promising Efficacy in KRAS-Mutated NSCLC

Trend towards better response rate, PFS compared with approved KRAS inhibitors

A photo of Environmental Protection Agency Administrator Michael Regan speaking at event at Howard University, in Washington.

EPA Bans Consumer Use of Toxic Chemical Known to Cause Liver, Lung Cancers

Methylene chloride has killed at least 88 workers since 1980

A menthol cigarette in an ashtray.

White House Indefinitely Delays Plan to Ban Menthol Cigarettes

Biden administration has delayed the final rule several times recently

FDA APPROVED alectinib (Alecensa) over a computer rendering of lung cancer.

Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC

The ALK inhibitor reduced the risk of recurrence or death by 76% versus chemotherapy

AACR over a photo of San Diego Convention Center in San Diego, CA

Accelerated Aging Linked to Recent Increase in Early-Onset Solid Tumors

Strength of association increased in more recent birth cohorts

1

鈥�